Senior Director, R&D Digital Enablement Lead jobs in United States
cer-icon
Apply on Employer Site
company-logo

CSL · 2 months ago

Senior Director, R&D Digital Enablement Lead

positionKing of Prussia, PA
timeFull-time
remoteHybrid
seniorityDirector/Executive
date12+ years exp

CSL Behring is a global biotherapeutics leader focused on saving lives through innovative therapies. The R&D Digital Enablement Lead is responsible for ensuring the adoption of digital transformation within R&D by driving agile delivery, change management, and process design.

BiotechnologyHealth CareHealth DiagnosticsMedical
check
Comp. & Benefits

Responsibilities

Lead business analysis and discovery to align TES digital projects with R&D priorities
Drive process design, reengineering, and operating model evolution for digital programs
Oversee agile delivery frameworks and support scrum teams as needed
Lead change management and communication strategies for adoption
Monitor value realization and build metrics frameworks to assess progress
Collaborate with R&D stakeholders to continuously improve digital workflows

Qualification

Digital transformationAgile deliveryChange managementBusiness analysisStakeholder engagementProcess designJiraSmartsheetMiro

Required

Bachelor's or Master's in Business, Life Sciences, or Technology-related field
12+ years of experience in digital transformation, business analysis, or change management
Proven success delivering agile initiatives in a global scientific or R&D setting
Experience with tools such as Jira, Smartsheet, Miro, or similar
Strong understanding of stakeholder engagement and adoption strategies

Company

CSL

twittertwittertwitter
Glassdoor4.6
company-logo
CSL develops innovative biotherapies and influenza vaccines that save lives, and help people with life-threatening medical conditions.
dateFounded in 1916
location
Melbourne, Victoria, AUS
people-size10001+ employees
web-link
https://www.csl.com

Funding

Current Stage
Public Company
Total Funding
$111M
2013-12-20Acquired
2004-02-06Post Ipo Equity· $111M
1994-06-03IPO

Leadership Team

leader-logo
Jeffrey Ball
Chief Sustainability Officer
linkedin
leader-logo
Joy Linton
Strategic Advisor
linkedin

Recent News

Pharma Letter
MHRA approves Kostaive mRNA COVID-19 vaccine
2026-01-03
MarketScreener
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years
2025-12-07
thefly.com
CSL just upgraded at Canaccord, here's why
2025-10-29
Company data provided by crunchbase